These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1167 related articles for article (PubMed ID: 30515680)

  • 1. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J
    Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago.
    Donenberg T; Ahmed H; Royer R; Zhang S; Narod SA; George S; Akbari MR; Ali J; Hurley J
    Breast Cancer Res Treat; 2016 Aug; 159(1):131-8. PubMed ID: 27469594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study.
    Nilsson MP; Nilsson ED; Borg Å; Brandberg Y; Silfverberg B; Loman N
    Breast Cancer Res Treat; 2019 Jan; 173(2):313-318. PubMed ID: 30311024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
    J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.
    Haanpää M; Pylkäs K; Moilanen JS; Winqvist R
    BMC Med Genet; 2013 Aug; 14():82. PubMed ID: 23941127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy.
    Apostolova C; Ferroum A; Alhassan B; Prakash I; Basik M; Boileau JF; Martel K; Meterissian S; Villareal Corpuz V; Wong N; Foulkes WD; Wong SM
    Eur J Surg Oncol; 2024 Jun; 50(6):108324. PubMed ID: 38636249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
    Stjepanovic N; Villacampa G; Nead KT; Torres-Esquius S; Melis GG; Nathanson KL; Teule A; Brunet J; Y Cajal TR; Llort G; Dienstmann R; Rue M; Domchek SM; Balmaña J
    Eur J Cancer; 2020 Jun; 132():53-60. PubMed ID: 32325420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
    Nilsson MP; Törngren T; Henriksson K; Kristoffersson U; Kvist A; Silfverberg B; Borg Å; Loman N
    Breast Cancer Res Treat; 2018 Feb; 168(1):117-126. PubMed ID: 29164420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
    Cerretini R; Mercado G; Morganstein J; Schiaffi J; Reynoso M; Montoya D; Valdéz R; Narod SA; Akbari MR
    Breast Cancer Res Treat; 2019 Dec; 178(3):629-636. PubMed ID: 31446535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.
    Benusiglio PR; Korenbaum C; Vibert R; Ezenfis J; Geoffron S; Paul C; Richard S; Byrde V; Lejeune M; Guillerm E; Basset N; Lotz JP; Chabbert-Buffet N; Gligorov J; Coulet F
    Eur J Med Genet; 2020 Dec; 63(12):104098. PubMed ID: 33186762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
    Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
    Chai X; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Tung N; Weitzel JN; Couch FJ; Hulick PJ; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Blum JL; Domchek SM; Chen J; Rebbeck TR
    Breast Cancer Res Treat; 2014 Nov; 148(2):397-406. PubMed ID: 25311111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing.
    Kwong A; Chu AT
    Asian Pac J Cancer Prev; 2012; 13(5):2241-7. PubMed ID: 22901201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.
    Silvestri V; Zelli V; Valentini V; Rizzolo P; Navazio AS; Coppa A; Agata S; Oliani C; Barana D; Castrignanò T; Viel A; Russo A; Tibiletti MG; Zanna I; Masala G; Cortesi L; Manoukian S; Azzollini J; Peissel B; Bonanni B; Peterlongo P; Radice P; Palli D; Giannini G; Chillemi G; Montagna M; Ottini L
    Cancer; 2017 Jan; 123(2):210-218. PubMed ID: 27648926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.
    Heemskerk-Gerritsen BA; Brekelmans CT; Menke-Pluymers MB; van Geel AN; Tilanus-Linthorst MM; Bartels CC; Tan M; Meijers-Heijboer HE; Klijn JG; Seynaeve C
    Ann Surg Oncol; 2007 Dec; 14(12):3335-44. PubMed ID: 17541692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The uptake of predictive DNA testing in 40 families with a pathogenic BRCA1/BRCA2 variant. An evaluation of the proband-mediated procedure.
    Menko FH; Jeanson KN; Bleiker EMA; van Tiggelen CWM; Hogervorst FBL; Ter Stege JA; Ait Moha D; van der Kolk LE
    Eur J Hum Genet; 2020 Aug; 28(8):1020-1027. PubMed ID: 32300191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas.
    Trottier M; Lunn J; Butler R; Curling D; Turnquest T; Royer R; Akbari MR; Donenberg T; Hurley J; Narod SA
    Clin Genet; 2015 Aug; 88(2):182-6. PubMed ID: 25060751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.